Vimarsana
Biggest News Aggregation in the World

Calico Life Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Calico Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Calico Life Sciences Today - Breaking & Trending Today

Calico Appoints Michael Lenardo, M.D., as Chief Scientific Officer - Vimarsana News

Calico Appoints Michael Lenardo, M.D., as Chief Scientific Officer

/PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on the biology of aging and age-related diseases, and founded by...

Chill, eat your vegetables and sleep: the art of ageing well - Vimarsana News

Chill, eat your vegetables and sleep: the art of ageing well

There's a joke that says staying healthy is simply the slowest possible way to die — but that doesn't mean it's not worth it in a world where people are living longer. Veruska De Vita has some tips

Reviewing ZIVO Bioscience (NASDAQ:ZIVO) and C4 Therapeutics (NASDAQ:CCCC) - Vimarsana News

Reviewing ZIVO Bioscience (NASDAQ:ZIVO) and C4 Therapeutics (NASDAQ:CCCC)

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) and ZIVO Bioscience (NASDAQ:ZIVO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Risk and Volatility C4 Therapeutics has a […]

Comparing Cosmo Pharmaceuticals (OTC:CMOPF) and AbbVie (NYSE:ABBV) - Vimarsana News

Comparing Cosmo Pharmaceuticals (OTC:CMOPF) and AbbVie (NYSE:ABBV)

Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk. Insider and Institutional Ownership 70.2% of AbbVie shares are […]

As ALS research booms, one treatment center finds itself in the spotlight - Vimarsana News

As ALS research booms, one treatment center finds itself in the spotlight

BioPharma